IP Library › Granted Patent US 12,331,122
Granted Patent B2
US 12,331,122 · App. 16/987,237 · Granted Jun 17, 2025

Anti-ASGR-1 monoclonal inhibitory antibodies

Inventors: Paul Nioi (Wellesley, MA); Peter Coward (San Francisco, CA); Christopher Murawsky (Vancouver, CA); Derek E. Piper (Santa Clara, CA); Fernando Garces (San Mateo, CA); Brian Mingtung Chan (Port Coquitlam, CA)
Assignee: Amgen Inc.
C07K16/2851A61K39/3955A61K2039/505A61K2039/507A61K45/06A61P3/06A61P9/04A61P9/10C07H21/02C07K14/705C07K14/7056C07K16/28C07K2317/21C07K2317/24C07K2317/30C07K2317/56C07K2317/565C07K2317/76C07K2317/77C07K2317/92C07K2317/94C12N15/1138
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,331,122
App. No.
16/987,237
Granted
Jun 17, 2025
Kind
B2
Abstract

Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.

Claims (48)

1. An isolated monoclonal antibody or antigen binding fragment thereof, wherein the isolated monoclonal antibody or antigen binding fragment thereof specifically binds to human asialoglycoprotein receptor 1 (“ASGR-1”) and comprises

a heavy chain variable domain comprising a VH CDR1, a VH CDR2 and a VH CDR3 and a light chain variable domain comprising a VL CDR1, a VL CDR2 and a VL CDR3, wherein:

(i) VH CDR1, VH CDR2, and VH CDR3 comprise the sequences of SEQ ID NOs: 4880, 12892, and 20904, respectively; and VL CDR1, VL CDR2 and VL CDR3 comprise the sequences of SEQ ID NOs: 872, 8884, and 16896, respectively;

(ii) VH CDR1, VH CDR2, and VH CDR3 comprise the sequences of SEQ ID NOs: 4700, 12712, and 20724, respectively; and VL CDR1, VL CDR2 and VL CDR3 comprise the sequences of SEQ ID NOs: 692, 8704, and 16716, respectively;

(iii) VH CDR1, VH CDR2, and VH CDR3 comprise the sequences of SEQ ID NOs: 5150, 13162, and 21174, respectively; and VL CDR1, VL CDR2 and VL CDR3 comprise the sequences of SEQ ID NOs: 1144, 9156, and 17168, respectively;

(iv) VH CDR1, VH CDR2, and VH CDR3 comprise the sequences of SEQ ID NOs: 7382, 15394, and 23406, respectively; and VL CDR1, VL CDR2 and VL CDR3 comprise the sequences of SEQ ID NOs: 3378, 11390, and 19402, respectively;

(v) VH CDR1, VH CDR2, and VH CDR3 comprise the sequences of SEQ ID NOs: 7822, 15834, and 23846, respectively; and VL CDR1, VL CDR2 and VL CDR3 comprise the sequences of SEQ ID NOs: 3818, 11830, and 19842, respectively;

(vi) VH CDR1, VH CDR2, and VH CDR3 comprise the sequences of SEQ ID NOs: 5378, 13390, and 21402, respectively; and VL CDR1, VL CDR2 and VL CDR3 comprise the sequences of SEQ ID NOs: 1372, 9384, and 17396, respectively;

(vii) VH CDR1, VH CDR2, and VH CDR3 comprise the sequences of SEQ ID NOs: 7500, 15512 and 23524, respectively; and VL CDR1, VL CDR2 and VL CDR3 comprise the sequences of SEQ ID NOs: 3496, 11508, and 19520, respectively;

(viii) VH CDR1, VH CDR2, and VH CDR3 comprise the sequences of SEQ ID NOs: 4846, 12858, and 20870, respectively; and VL CDR1, VL CDR2 and VL CDR3 comprise the sequences of SEQ ID NOs: 838, 8850, and 16862, respectively;

(ix) VH CDR1, VH CDR2, and VH CDR3 comprise the sequences of SEQ ID NOs: 6138, 14150, and 22162, respectively; and VL CDR1, VL CDR2 and VL CDR3 comprise the sequences of SEQ ID NOs: 2132, 10144, and 18156, respectively;

(x) VH CDR1, VH CDR2, and VH CDR3 comprise the sequences of SEQ ID NOs: 6884, 14896, and 22908, respectively; and VL CDR1, VL CDR2 and VL CDR3 comprise the sequences of SEQ ID NOs: 2878, 10890, and 18902, respectively;

(xi) VH CDR1, VH CDR2, and VH CDR3 comprise the sequences of SEQ ID NOs: 6898, 14910, and 22922, respectively; and VL CDR1, VL CDR2 and VL CDR3 comprise the sequences of SEQ ID NOs: 2892, 10904, and 18916, respectively;

(xii) VH CDR1, VH CDR2, and VH CDR3 comprise the sequences of SEQ ID NOs: 7296, 15308, and 23320, respectively; and VL CDR1, VL CDR2 and VL CDR3 comprise the sequences of SEQ ID NOs: 3292, 11304, and 19316, respectively;

(xiii) VH CDR1, VH CDR2, and VH CDR3 comprise the sequences of SEQ ID NOs: 7298, 15310, and 23322, respectively; and VL CDR1, VL CDR2 and VL CDR3 comprise the sequences of SEQ ID NOs: 3294, 11306, and 19318, respectively;

(xiv) VH CDR1, VH CDR2, and VH CDR3 comprise the sequences of SEQ ID NOs: 7308, 15320, and 23332, respectively; and VL CDR1, VL CDR2 and VL CDR3 comprise the sequences of SEQ ID NOs: 3304, 11316, and 19328, respectively; or

(xv) VH CDR1, VH CDR2, and VH CDR3 comprise the sequences of SEQ ID NOs: 6508, 14520, and 22532, respectively; and VL CDR1, VL CDR2 and VL CDR3 comprise the sequences of SEQ ID NOs: 2502, 10514, and 18526, respectively.

2. The isolated monoclonal antibody or antigen binding fragment thereof of claim 1 , comprising a heavy chain variable domain having at least 80% identity to any of the VH domain amino acid sequences set forth in SEQ ID NOs: 28734, 29184, 31418, 31858, 29412, 31536, 28914, 28880, 30172, 31332, 31334, 31344, 30542, 30918, and 30932.

3. The isolated monoclonal antibody or antigen binding fragment thereof of claim 1 , comprising a heavy chain variable domain having at least 90% identity to any of the VH domain amino acid sequences set forth in SEQ ID NOs: 28734, 29184, 31418, 31858, 29412, 31536, 28914, 28880, 30172, 31332, 31334, 31344, 30542, 30918, and 30932.

4. The isolated monoclonal antibody or antigen binding fragment thereof of claim 1 , comprising a light chain variable domain having at least 80% identity to any of the VL domain amino acid sequences set forth in SEQ ID NOs: 24728, 25178, 27412, 27852, 25406, 27530, 24908, 24874, 26166, 27326, 27328, 27338, 26536, 26912, and 26926.

5. The isolated monoclonal antibody or antigen binding fragment thereof of claim 1 , comprising a light chain variable domain having at least 90% identity to any of the VL domain amino acid sequences set forth in SEQ ID NOs: 24728, 25178, 27412, 27852, 25406, 27530, 24908, 24874, 26166, 27326, 27328, 27338, 26536, 26912, and 26926.

6. The isolated monoclonal antibody or antigen binding fragment thereof of claim 1 , wherein the heavy chain variable domain and the light chain variable domain are selected from one of the following paired VH and VL sequences, respectively:

SEQ ID NOs: 28734 and 24728;

SEQ ID NOs: 29184 and 25178;

SEQ ID NOs: 31418 and 27412;

SEQ ID NOs: 31858 and 27852;

SEQ ID NOs: 29412 and 25406;

SEQ ID NOs: 31536 and 27530;

SEQ ID NOs: 28914 and 24908;

SEQ ID NOs: 28880 and 24874;

SEQ ID NOs: 30172 and 26166;

SEQ ID NOs: 31332 and 27326;

SEQ ID NOs: 31334 and 27328;

SEQ ID NOs: 31344 and 27338;

SEQ ID NOs: 30542 and 26536;

SEQ ID NOs: 30918 and 26912; and

SEQ ID NOs: 30932 and 26926.

7. The isolated monoclonal antibody or antigen binding fragment thereof of claim 1 that is a humanized or a human monoclonal antibody or antigen binding fragment thereof.

8. An isolated neutralizing monoclonal antibody that binds to human asialoglycoprotein receptor 1 (“ASGR-1”) comprising the amino acid sequence of SEQ ID NO:5 but has a statistically significant reduction in binding to a variant human ASGR-1, wherein the variant human ASGR-1 comprises a single mutation of a residue selected from the group consisting of: R170, S171, G172, R183, L184, W195, E196, K199, H203, H204, P207, V208, N209, H215, D216, P220, D225, D228, R237, P238, E239, P241, D242, D243, Y245, G246, H247, G248, L249, G251, E253, T259, D260, R263, N265, Q270, R271, P272, R274 and E280 as shown in SEQ ID NO:5.

9. The isolated neutralizing monoclonal antibody of claim 8 , wherein the single mutation is selected from the group consisting of: W195, E196, K199, H203, H204, P207, P220, G251, and R263 as shown in SEQ ID NO:5.

10. The isolated monoclonal antibody of claim 8 , wherein the single mutation comprises a substitution of a non-arginine residue with arginine, or a substitution of an arginine residue to glutamic acid.

11. The isolated monoclonal antibody of claim 9 , wherein the single mutation comprises a substitution of a non-arginine residue with arginine, or a substitution of an arginine residue to glutamic acid.

12. An isolated humanized or human monoclonal antibody that binds to human asialoglycoprotein receptor 1 (“ASGR-1”) comprising the amino acid sequence of SEQ ID NO: 5, wherein the binding of the monoclonal antibody to human ASGR-1 is reduced at a pH of 5.6 as compared to its binding at a pH of 7.4, and wherein the monoclonal antibody inhibits ASGR-1 ligand binding.

13. The isolated humanized or human monoclonal antibody of claim 12 , wherein the binding of the monoclonal antibody to human ASGR-1 is reduced in the absence of calcium as compared to its binding in the presence of calcium.

14. A pharmaceutical composition comprising the isolated monoclonal antibody or antigen binding fragment thereof of claim 1 , and a pharmaceutically acceptable excipient.

15. A pharmaceutical composition comprising the isolated monoclonal antibody of claim 8 , and a pharmaceutically acceptable excipient.

16. A pharmaceutical composition comprising the isolated monoclonal antibody of claim 12 , and a pharmaceutically acceptable excipient.

17. A pharmaceutical composition comprising the isolated monoclonal antibody of claim 13 , and a pharmaceutically acceptable excipient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2020
From: NIOI, PAUL; COWARD, PETER; PIPER, DEREK E.; GARCES, FERNANDO; ZHANG, JUN; LI, YANG; MURAWSKY, CHRISTOPHER; CHAN, BRIAN MINGTUNG
To: AMGEN INC.
Reel/Frame 054406/0061 →
Continuity (6)
Continuation 16230356 · Dec 21, 2018
Division 15279162 · Sep 28, 2016
Provisional Application 62319740 · Apr 7, 2016
Provisional Application 62259553 · Nov 24, 2015
Provisional Application 62234546 · Sep 29, 2015
Related Publication 20210163601A1 · Jun 3, 2021
References Cited (400)
US 3720760A · Wide et al. · 1973 [cited by applicant]
US 4179337A · Davis et al. · 1979 [cited by applicant]
US 4301144A · Iwashita et al. · 1981 [cited by applicant]
US 4331647A · Goldenberg · 1982 [cited by applicant]
US 4496689A · Mitra · 1985 [cited by applicant]
US 4518584A · Mark et al. · 1985 [cited by applicant]
US 4522811A · Eppstein et al. · 1985 [cited by applicant]
US 4640835A · Shimizu et al. · 1987 [cited by applicant]
US 4670417A · Iwasaki et al. · 1987 [cited by applicant]
US 4737456A · Weng et al. · 1988 [cited by applicant]
US 4737462A · Mark et al. · 1988 [cited by applicant]
US 4751180A · Cousens et al. · 1988 [cited by applicant]
US 4791192A · Nakagawa et al. · 1988 [cited by applicant]
US 4935233A · Bell et al. · 1990 [cited by applicant]
US 5011912A · Hopp et al. · 1991 [cited by applicant]
US 5208020A · Chari et al. · 1993 [cited by applicant]
US 5223409A · Ladner et al. · 1993 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5416064A · Chari et al. · 1995 [cited by applicant]
US 5457035A · Baum et al. · 1995 [cited by applicant]
US 5474981A · Leder et al. · 1995 [cited by applicant]
US 5475092A · Chari et al. · 1995 [cited by applicant]
US 5539082A · Nielson et al. · 1996 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5585499A · Chari et al. · 1996 [cited by applicant]
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 5627052A · Schrader · 1997 [cited by applicant]
US 5693762A · Queen · 1997 [cited by examiner]
US 5698426A · Husebird · 1997 [cited by applicant]
US 5714331A · Buchardt et al. · 1998 [cited by applicant]
US 5719262A · Buchardt et al. · 1998 [cited by applicant]
US 5814318A · Lonberg et al. · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5859205A · Adair et al. · 1999 [cited by applicant]
US 5869619A · Studnicka · 1999 [cited by applicant]
US 5877293A · Adair et al. · 1999 [cited by applicant]
US 5877397A · Lonberg et al. · 1999 [cited by applicant]
US 5886152A · Nakatani et al. · 1999 [cited by applicant]
US 5898031A · Crooke · 1999 [cited by applicant]
US 6054297A · Carter et al. · 2000 [cited by applicant]
US 6107094A · Crooke · 2000 [cited by applicant]
US 6133426A · Gonzalez et al. · 2000 [cited by applicant]
US 6168587B1 · Bellhouse et al. · 2001 [cited by applicant]
US 6194389B1 · Johnston et al. · 2001 [cited by applicant]
US 6210924B1 · Hu et al. · 2001 [cited by applicant]
US 6277375B1 · Ward · 2001 [cited by applicant]
US 6340701B1 · Chari et al. · 2002 [cited by applicant]
US 6372738B2 · Chari et al. · 2002 [cited by applicant]
US 6395272B1 · Deo et al. · 2002 [cited by applicant]
US 6436931B1 · Chari et al. · 2002 [cited by applicant]
US 6471996B1 · Sokoll et al. · 2002 [cited by applicant]
US 6472375B1 · Hoon et al. · 2002 [cited by applicant]
US 6506559B1 · Fire et al. · 2003 [cited by applicant]
US 6573099B2 · Graham · 2003 [cited by applicant]
US 6602684B1 · Umana et al. · 2003 [cited by applicant]
US 6693187B1 · Dellinger · 2004 [cited by applicant]
US 6696245B2 · Winter et al. · 2004 [cited by applicant]
US 6703199B1 · Koide · 2004 [cited by applicant]
US 6846634B1 · Tomlinson et al. · 2005 [cited by applicant]
US 6881557B2 · Foote · 2005 [cited by applicant]
US 7029872B2 · Gerngross · 2006 [cited by applicant]
US 7056704B2 · Tuschl et al. · 2006 [cited by applicant]
US 7064244B2 · Jakobovits et al. · 2006 [cited by applicant]
US 7078196B2 · Tuschl et al. · 2006 [cited by applicant]
US 7563459B2 · Phillips · 2009 [cited by applicant]
US 7579451B2 · Manoharan et al. · 2009 [cited by applicant]
US 7695963B2 · Agulnick et al. · 2010 [cited by applicant]
US 8030457B2 · Jackson et al. · 2011 [cited by applicant]
US 8394628B2 · Tuschl et al. · 2013 [cited by applicant]
US 8502014B2 · Grosveld · 2013 [cited by applicant]
US 8507455B2 · Manoharan et al. · 2013 [cited by applicant]
US 8507748B2 · Grosveld · 2013 [cited by applicant]
US 8871723B2 · Rubinstein et al. · 2014 [cited by applicant]
US 8877917B2 · Forst et al. · 2014 [cited by applicant]
US 9006292B2 · Raghavan · 2015 [cited by applicant]
US 9181551B2 · McSwiggen et al. · 2015 [cited by applicant]
US 10358497B2 · Nioi et al. · 2019 [cited by applicant]
US 11066472B2 · Nioi et al. · 2021 [cited by applicant]
US 20010036459A1 · Ravetch · 2001 [cited by applicant]
US 20030039958A1 · Holt et al. · 2003 [cited by applicant]
US 20030133939A1 · Ledbetter et al. · 2003 [cited by applicant]
US 20040009507A1 · Winter et al. · 2004 [cited by applicant]
US 20040038291A2 · Tomlinson et al. · 2004 [cited by applicant]
US 20040072290A1 · Umana et al. · 2004 [cited by applicant]
US 20040185045A1 · Koenig et al. · 2004 [cited by applicant]
US 20040202995A1 · De Wildt et al. · 2004 [cited by applicant]
US 20040261148A1 · Dickey et al. · 2004 [cited by applicant]
US 20050079605A1 · Umana et al. · 2005 [cited by applicant]
US 20050118643A1 · Burgess et al. · 2005 [cited by applicant]
US 20050202512A1 · Tomlinson et al. · 2005 [cited by applicant]
US 20050238646A1 · Ledbetter et al. · 2005 [cited by applicant]
US 20050272128A1 · Umana et al. · 2005 [cited by applicant]
US 20060039904A1 · Wu et al. · 2006 [cited by applicant]
US 20060040325A1 · Wu et al. · 2006 [cited by applicant]
US 20060067930A1 · Adams et al. · 2006 [cited by applicant]
US 20060257399A1 · Gerngross et al. · 2006 [cited by applicant]
US 20070031402A1 · Zhang et al. · 2007 [cited by applicant]
US 20070092521A1 · McPherson et al. · 2007 [cited by applicant]
US 20090028856A1 · Chen et al. · 2009 [cited by applicant]
US 20090169548A1 · Grosveld et al. · 2009 [cited by applicant]
US 20090274713A1 · Chari et al. · 2009 [cited by applicant]
US 20090285805A1 · Grosveld et al. · 2009 [cited by applicant]
US 20090307787A1 · Grosveld et al. · 2009 [cited by applicant]
US 20110092565A1 · Bumcrot et al. · 2011 [cited by applicant]
US 20110314563A1 · Craig et al. · 2011 [cited by applicant]
US 20120028596A1 · Yamada et al. · 2012 [cited by applicant]
US 20120151610A1 · Craig et al. · 2012 [cited by applicant]
US 20130024961A1 · Burlak et al. · 2013 [cited by applicant]
US 20150135344A1 · Tector, III et al. · 2015 [cited by applicant]
US 20150197746A1 · Rajeev et al. · 2015 [cited by applicant]
US 20150259689A1 · Kowalik et al. · 2015 [cited by applicant]
US 20160122761A1 · Prakash et al. · 2016 [cited by applicant]
US 20170088620A1 · Nioi et al. · 2017 [cited by applicant]
US 20190248902A1 · Nioi et al. · 2019 [cited by applicant]
US 20190309306A1 · Ollmann et al. · 2019 [cited by applicant]
CN 104418950A · 2015 [cited by applicant]
EP 404097 · 1991 [cited by applicant]
EP 1144623 · 2001 [cited by applicant]
EP 439095 · 2004 [cited by applicant]
JP H04356198A · 1992 [cited by applicant]
KR 1020050024757A · 2005 [cited by applicant]
WO WO8705330 · 1987 [cited by applicant]
WO WO9202551 · 1992 [cited by applicant]
WO WO9310151 · 1993 [cited by applicant]
WO WO9311161 · 1993 [cited by applicant]
WO WO9321232 · 1993 [cited by applicant]
WO WO9410308 · 1994 [cited by applicant]
WO WO9734631 · 1997 [cited by applicant]
WO WO9823289 · 1998 [cited by applicant]
WO WO9824838 · 1998 [cited by applicant]
WO WO9951642 · 1999 [cited by applicant]
WO WO9958572 · 1999 [cited by applicant]
WO WO0076310 · 2000 [cited by applicant]
WO WO0179299 · 2001 [cited by applicant]
WO WO03011878 · 2003 [cited by applicant]
WO WO2004016750 · 2004 [cited by applicant]
WO WO2004029207 · 2004 [cited by applicant]
WO WO2004063351 · 2004 [cited by applicant]
WO WO2005044859 · 2005 [cited by applicant]
WO WO2005084390 · 2005 [cited by applicant]
WO WO2005694879 · 2005 [cited by applicant]
WO WO2006071280 · 2006 [cited by applicant]
WO WO2006071856 · 2006 [cited by applicant]
WO WO2008122886 · 2008 [cited by applicant]
WO WO2009013620 · 2009 [cited by applicant]
WO WO2009089004 · 2009 [cited by applicant]
WO WO2009099728 · 2009 [cited by applicant]
WO WO2011068798A1 · 2011 [cited by applicant]
WO WO2014023709A1 · 2014 [cited by applicant]
WO WO2017058944A1 · 2017 [cited by applicant]
WO WO2018039647 · 2018 [cited by applicant]
Born, Sep. 2005, “Benefits and Application of Antibodies Against the H1 Carbohydrate Recognition Domain of the Human Hepatic Asialoglycoprotein Receptor”, Dissertation, 324 pages as published. [cited by examiner]
NCBI Record for P07036, dated Feb. 23, 2022, 6 pages as printed, no author indicated; available on-line at www.ncbi.nlm.nih.gov/protein/P07036. [cited by examiner]
Benjamini et al, 1991. Immunology: A Short Course, 2nd edition, p. 40 only. [cited by examiner]
Ferrara et al (2015. mAbs. 7(1): 32-41). [cited by examiner]
Adams et al., PHENIX: a comprehensive Python-based system for macromolecular structure solution, Acta crystallographica vol. 66, pp. 213-221 (2010). [cited by applicant]
Albert et al., The B-cell Epitope of the Monoclonal Anti-Factor VIII Antibody ESH8 Characterized by Peptide Array Analysis, Thromb Haemost vol. 99, pp. 634-637 (2008). [cited by applicant]
Alting-Mees et al., Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridisms Strategies in Molecular Biology vol. 3, 1990). [cited by applicant]
Andrews et all Fragmentation of Immunoglobulin G, Current Protocols in Immunology, Unit 2.10A John Wiley & Sons (1997). [cited by applicant]
Aoki et al., Potential tumor-targeting peptide vector of histidylated oligolysine conjugated to a tumor-homing RGD motif, Cancer Gene Therapy vol. 8, pp. 783-787 (2001). [cited by applicant]
Aplin et al., Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids, CRC Critical Reviews in Biochemistry, pp. 259-306, May 1981. [cited by applicant]
Arbones et al., Lymphocyte Homing and Leukocyte Rolling and Migration Are Impaired in L-Selectin-Deficient Mice, Immunity. vol. 1, pp. 247-260 (1994). [cited by applicant]
Ashkenazi et al., Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin, Proceedings of the National Academy of Sciences USA, vol. 88, pp. 10535-10539, Dec. 1991. [cited by applicant]
Ashwell et al., “Carbohydrate-Specific Receptors of the Liver,” Annual Review of Biochemistry, vol. 51, pp. 531-554. 1982. [cited by applicant]
Ausubel et al., Table of Contents of “Current Protocols in Molecular Biology,” Book: Short Protocols in Molecular Biology, 2 ed., Greene Publishing Associates and John Wiley & Sons, 1992. [cited by applicant]
Babcock et al., A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities, Proc. Natl. Acad. Sci. USA vol. 93, pp. 843-848 (1996). [cited by applicant]
Baines et al., Purification of Immunoglobulin G (IgG), Methods in Molecular Biology vol. 10, pp. 79-104, The Human Press Inc. (1992). [cited by applicant]
Baron et al., Co-regulation of two gene activities by tetracycline via a bidirectional promoter, Nucleic Acids Res. vol. 23, pp. 3605-3606 (1995). [cited by applicant]
Baum et al., “Molecular Characterization of Murine and Human OX40/OX40 Ligand Systems: Identification of a Human OX40 Ligand as the HTLV-1-Regulated Protein GP34,” The EMBO Journal, vol. 13, No. 17, pp. 3992-4001, 1994. [cited by applicant]
Battye et al., iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM, Acta crystallographica vol. 67, pp. 271-281 (2011). [cited by applicant]
Bauer et al., A genetic enrichment for mutations constructed by oligodeoxynucleotide-directed mutagenesis Gene vol. 37, pp. 73 (1985). [cited by applicant]
Bebbington et al., The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells, DNA Cloning, vol. 3. Academic Press (1987). [cited by applicant]
Bird et al., “Single-Chain Antigen-Binding Proteins,” Science, vol. 242, pp. 423-426, 1988. [cited by applicant]
Bishop, Table of Contents of Guide to Huge Computers, ed., Academic Press, (1994). [cited by applicant]
Bowie et al., “A Method to Identify Protein Sequences That Fold Into a Known Three-Dimensional Structure,” Science, vol. 253, pp. 164-170, Jul. 12, 1991. [cited by applicant]
Bloom et al., “Intrachain Disulfide Bond in the Core Hinge Region of Human IgG4,” Protein Science, vol. 6, pp. 407-415, 1997. [cited by applicant]
Boerner et al., Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes Journal or Immunology vol. 147, pp. 86-95 (1991). [cited by applicant]
Born, R., Benefit and Application of Antibodies Against the HI Carbohydrate Recognition Domain of the Human Hepatic Asialoglycoprotein Receptor High Yield Recombinant Production of the HI Carbohydrate Recognition Domain… [cited by applicant]
Branden et al., Table of Contents of “Introduction to Protein Structure,” Garland Publishing, Inc., 6 pages, 1991. [cited by applicant]
Bruggemann et al., Production of human antibody repertoires in transgenic mice Current Opinions in Biotechnology vol. 8, pp. 455-458 (1997). [cited by applicant]
Burger et al., Human plasma R-type vitamin B12-binding proteins II. The role of transcobalamin I, transcobalamin III, and the normal granulocyte vitamin B12-binding protein in the plasma transport of vitamin B12, The Jo… [cited by applicant]
Burton et al., “Human Antibodies from Combinatorial Libraries,” Advances in Immunology, vol. 57, pp. 191-280, 1994. [cited by applicant]
Byrn et al., “Biological Properties of a CD4 Immunoadhesion,” Nature, vol. 344, pp. 667-670, Apr. 12, 1990. [cited by applicant]
Cao et al., “Characterization of a Single-Chain Variable Fragment (scFv) Antibody Directed Against the Human Asialoglycoprotein Receptor,” Biotechnology and Applied Biochemistry, vol. 44, No. 2, pp. 65-72, 2006. [cited by applicant]
Carrillo, et al., “The Multiple Sequence Alignment Problem in Biology,”SIAM Journal on Applied Mathematics, vol. 48,, No. 5, pp. 1073-1082, Oct. 5, 1988. [cited by applicant]
CCP4, The CCP4 suite: programs for protein crystallography, Acta crystallographica vol. 50, pp. 760-763 (1994). [cited by applicant]
Chambers et al., Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma, Nature genetics vol. 43, pp. 1131-1138 (2011). [cited by applicant]
Chen et al., Immunoglobulin gene rearrangement in B-cell deficient mice generated by targeted deletion of the JH locus, International Immunology vol. 5, pp. 647-656 (1993). [cited by applicant]
Cheung et al., Epitope-Specific Antibody Response to the Surface Antigen of Duck Hepatitis 6 Virus in Infected Ducks Virology vol. 176, pp. 546-552 (1990). [cited by applicant]
Choi et al., Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome, Nature Genetics vol. 4, pp. 117-123 (1993). [cited by applicant]
Chothia, C et al., Canonical Structures for the Hypervariable Regions of Immunoglobulins, Journal of Molecular Biology vol. 196, pp. 901-917 (1987). [cited by applicant]
Chothia et al., Conformations of Immunoglobulin hypervariable regions, Nature vol. 342, pp. 878-883 (1989). [cited by applicant]
Chou et al., Prediction of the secondary structure of proteins from their amino acid sequence, Adv. Enzymol. Relat. Areas Mol. Biol. vol. 47, pp. 45-148 (1978). [cited by applicant]
Chou et al., Empirical predictions of protein conformation, Ann. Rev. Biochem. vol. 47, pp. 251-276. [cited by applicant]
Chou et al., Prediction of protein conformation, Biochemistry vol. 13(2), pp. 222-245 (1974). [cited by applicant]
Chou et al. Prediction of A-Turns, Biophys J. vol. 26, pp. 367-384 (1979). [cited by applicant]
Chou et al., Conformational Parameters for amino acids in helical b-sheet, and random coil regions calculated from proteins, Biochemistry vol. 113(2), pp. 211-222 (1974). [cited by applicant]
Clark, M., Antibody humanization: a case of the ‘Emperor's new clothes’? Immunology Today vol. 21(8), pp. 397-402 (2000). [cited by applicant]
Coates et al., Epitope mapping by amide hydrogen/deuterium exchange coupled with immobilization of antibody, on-line proteolysis, liquid chromatography and mass spectrometry, Rapid Communication Mass Pectrometry vol. 23… [cited by applicant]
Cockett et al., High level of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification, Bio/Technology vol. 8, pp. 2 (1990). [cited by applicant]
Colberre-Garapin et al., A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells J. Mol. Biol. vol. 150, pp. 1 (1981). [cited by applicant]
Cortez-Retamozo et al., Efficient Cancer Therapy with a Nanobody-Based Conjugate, Cancer Research vol. 64, pp. 2853-2857 (2004). [cited by applicant]
Courtenay-Luck, Genetic Manipulation of Monoclonal Antibodies, Monoclonal Antibodies: Production, Engineering and Clinical Application, Ritter et al. (eds.), pp. 166, Cambridge University Press (1995). [cited by applicant]
Craik, Use of oligonucleotides for site-specific mutagenesis, BioTechniques, 12-19 (1985). [cited by applicant]
Crameri et al., DNA shuffling of a family of genes from diverse species accelerates directed evolution, Nature vol. 391, pp. 288-291 (1998). [cited by applicant]
Creighton, Ed., Proteins, Structures, and Molecular Principles, W.H. Freeman and Company (1984). [cited by applicant]
Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., pp. 79-86 (1983). [cited by applicant]
Crouse et al., Expression and Amplification of Engineered Mouse Dihydrofolate Reductase Minigenes, Mol. Cell. Biol. vol. 3, pp. 257 (1983). [cited by applicant]
Cunningham and Wells, High-resolution epitope mapping og HGH-receptor interactions by alanine-scanning mutagenesis, Science vol. 244, pp. 1081085 (1989). [cited by applicant]
D'Souza et al., Asialoglycoprotein receptor mediated hepatocyte targeting—Strategies and applications Journal of Control Release vol. 203, pp. 126-139 (2015). [cited by applicant]
Dall'Acqua et al., Antibody humanization by framework shuffling, Methods vol. 36(1), pp. 43-60 (2005). [cited by applicant]
Davis et al., Transgenic mice as a source of fully human antibodies for the treatment of cancer, Cancer Metastasis Rev. vol. 18, pp. 421-425 (1999). [cited by applicant]
Davis et al., Production of human antibodies from transgenic mice in Lo, ed. Antibody Engineering: Methods and Protocols, Humana Press, NJ, pp. 191-200 (2003). [cited by applicant]
Deleavey et al., Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing Chemistry and Biology, vol. 19, pp. 937-954 (2012). [cited by applicant]
Devereux et al., A comprehensive set of sequence analysis programs for the VAX, Nucl. Acids Res. vol. 12(1), pp. 387 (1984). [cited by applicant]
Di Angelantonio et al., Major lipids, apolipoproteins, and risk of vascular disease, Jama vol. 302, pp. 1993-2000 (2009). [cited by applicant]
Do et al., Common variants associated with plasma triglycerides and risk for coronary artery disease. Nature genetics vol. 45, pp. 1345-1352 (2013). [cited by applicant]
Dracopoli et al. (eds), Table of Contents of Current Protocols in Human Genetics, John Wiley & Sons (1994). [cited by applicant]
Emsley et al., Features and development of Coot, Acta crystallographica vol. 66, pp. 486-501 (2010). [cited by applicant]
Evans, Scaling and assessment of data quality, Acta crystallographica vol. 62, pp. 72-82 (2006). [cited by applicant]
Fanslow et al., Structural characteristics of CD40 ligand that determine biological function , Semin. Immunol. vol. 6, pp. 267-278 (1994). [cited by applicant]
Fell et al., Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab′) with specificity for carcinomas and human IL-2., J. Immunol. vol. 146, pp. 2446-2452 (1991). [cited by applicant]
Fieser et al., Table of Contents of Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994). [cited by applicant]
Fishwild et al., High-avidity human IgGk monoclonal antibodies from a novel strain of miniolocus transgenic mice Nature Biotechnology vol. 14, pp. 845-851 (1996). [cited by applicant]
Foecking et al., Powerful and versatile enhancer-promoter unit for mammalian expression vectors Gene vol. 45, pp. 101 (1986). [cited by applicant]
Fredericks et al., Identification of potent human anti-IL-1RI antagonist antibodies, Protein Engineering, Design, & Selection vol. 17, pp. 95-106 (2004). [cited by applicant]
Friedewald et al., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. vol. 18, pp. 499-502 (1972). [cited by applicant]
Furger et al., Comparison of recombinant human haptocorrin expressed in human embryonic kidney cells and native haptocorrin PloS one vol. 7, e37421 (2012). [cited by applicant]
Gallo et al., The human immunoglobulin loci introduced into mice: V (D) and J gene segment usage similar to that of adult humans European Journal of Immunology vol. 30, pp. 534-540 (2000). [cited by applicant]
Gentz et al., Bioassay for trans-activation using purified human immunodeficiency virus tat-encoded protein: Trans-activation requires mRNA synthesis Proc. Natl. Acad. Sci. USA vol. 86, pp. 821-824 (1989). [cited by applicant]
Gerhardt et al. Structure of IL-17A in complex with a potent, fully human neutralizing antibody, Journal of Molecular Biology vol. 394, pp. 905-921 (2009). [cited by applicant]
Gibskov et al., Profile analysis: Detection of distantly related proteins. Proc. Nat. Acad. Sci. vol. 84(13), pp. 4355-4358 (1987). [cited by applicant]
Gillies et al., Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells, Proc. Natl. Acad. Sci. vol. 89, pp. 1428-1432 (1992). [cited by applicant]
Glasky et al., Stability of Specific Immunoglobulin Secretion by EBV-Transformed Lymphoblastoid Cells and Human-Murine Heterohybridomas, Hybridoma vol. 8, pp. 377-389 (1989). [cited by applicant]
Gluzman et al., SV40-Transformed Simian Cells Support the Replication of Early SV40 Mutants, Cell vol. 23, pp. 175 (1981). [cited by applicant]
Goeddel, Gene Expression Technology: Methods in Enzymology vol. 185, Academic Press, (1990). [cited by applicant]
Gold et al., Aptamer-based multiplexed proteomic technology for biomarker discovery, PLoS One 5, e15004, doi:10.1371/journal.pone.0015004 (2010). [cited by applicant]
Green et al., Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs Nat Genet. vol. 7, pp. 13-21 (1994). [cited by applicant]
Green et al., Regulation of B Cell Development by Variable Gene Complexity in Mice Reconstituted with Human Immunoglobulin Yeast Artificial Chromosomes, Journal of Experimental Medicine vol. 188, pp. 483-495 (1998). [cited by applicant]
Green, Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies, Journal of Immunological Methods vol. 231, pp. 11-2… [cited by applicant]
Greene et al., Protection for the hydroxyl group, including 1, 2- and 1,3-diols, Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons (1991). [cited by applicant]
Gretarsdottir et al., Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm, Nature genetics vol. 42, pp. 692 (2010). [cited by applicant]
Gretarsdottir et al., The gene encoding phosphodiesterase 4D confers risk of ischemic stroke, Nature genetics vol. 35, pp. 131-138 (2003). [cited by applicant]
Grewal, The Ashwell-Morell Receptor, Methods in Enzymology vol. 479, chapter 13, pp. 223-241 (2010). [cited by applicant]
Gribskov et al., Profile Analysis, Meth. Enzym. vol. 183, pp. 146-159 (1990). [cited by applicant]
Gribskov et al., Sequence analysis primer, eds., M Stockton Press, (1991). [cited by applicant]
Griffin, et al., Computer analysis of sequence data, part I, eds., Humana Press, (1994). [cited by applicant]
Gu et al. The asialoglycoprotein receptor suppresses the metastasis of hepatocellular carcinoma via LASS2-mediated inhibition of V-ATPase activity, Cancer Letters, vol. 379, pp. 107-116, (2016). [cited by applicant]
Gudbartssoon et al., Large Scale whole-genome sequencing of the Icelandic population, Nature Genetics vol. 47(5), pp. 435-444 (2015). [cited by applicant]
Haddad et al., Evidence for a third genetic locus causing familial hypercholesterolemia. A non-LDLR, non-APOB kindred, Journal of lipid research vol. 40, pp. 1113-1122 (1999). [cited by applicant]
Hamajima et al. Intranasal Administration of HIV-DNA vaccine formulated with a polymer, carboxymethycellulose, augments mucosal antibody production and cell-mediated immune response , Clin. Immunol. Immunopathol. vol. 8… [cited by applicant]
Harding et al., “Class Switching in Human Immunoglobulin Transgenic Mice,” Annals of the New York Academy of Sciences, vol. 764, pp. 536-546, 1995. [cited by applicant]
Hardonk al., A Histochemical Study about the zonal distribution of galactose-biding protein in rat liver, Histochemistry vol. 69(3), pp. 289-297 (1980). [cited by applicant]
Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Laboratory Press (1988 and 1990). [cited by applicant]
Harris, Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture Journal of Chromatography vol. 705, pp. 129-134 (1995). [cited by applicant]
Haubner et al. Glycosylated RGD-Containing Peptides: Tracer for Tumor Targeting and Angiogenesis Imaging with Improved Biokinetics, Jour. Nucl. Med. vol. 42, pp. 326-336 (2001). [cited by applicant]
Hollenbaugh et al., Construction of Immunoglobulin Fusion Proteins, Current Protocols in Immunology, Suppl. 4, pp. 10.19.1-10.19.11. (1992). [cited by applicant]
Hollinger and Hudson, Engineered antibody fragments and the rise of single domains, Nature Biotechnology vol. 23(9), pp. 1126-1136 (2005). [cited by applicant]
Hollinger et al. “Diabodies”: Small bivalent and bispecific antibody fragments, Proc. Natl. Acad. Sci. USA vol. 90, pp. 6444-6448 (1993). [cited by applicant]
Holm et al., Protein folds and families: sequence and structure alignments, Nucl. Acid. Res. vol. 27(1), pp. 244-247 (1999). [cited by applicant]
Honegger and Pluckthun, Yet another numbering scheme for immunoglobulin variable domains: An automatic modeling and analysis tool, Journal of Molecular Biology vol. 309(3), pp. 657-670 (2001). [cited by applicant]
Hoogenboom et al., Human antibodies from synthetic repertories of germline VH Gene Segments Rearranged in vitro Journal of Molecular Biology vol. 227, pp. 381-388 (1992). [cited by applicant]
Hoogendoorn et al., Thyroid function and prevalence of anti-thyroperoxidase antibodies in a population with borderline sufficient iodine intake: influences of age and sex, Clinical chemistry vol. 52, pp. 104-111 (2006). [cited by applicant]
Hopp et al. A Short Polypeptide Marker Sequence useful for recombinant protein identification and purification, Bio/Technology vol. 6, pp. 1204 (1988). [cited by applicant]
Hoppe et al., A parallel three stranded o-helical bundle at the nucleation site of collagen triple-helix formation, FEBS Letters vol. 344, pp. 191 (1994). [cited by applicant]
Hudson et al., Sodium-coupled glycine uptake by Ehrlich ascites tumor cells results in an increase in cell volume and plasma membrane channel activities, Proc. Natl. Acad. Sci. USA vol. 85, pp. 5879-5883 (1988). [cited by applicant]
Hunt et al., Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred, Arterioscler Thromb Vasc Biol vol. 20, pp. 1089-1093 (2000). [cited by applicant]
Huse et al., Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda, Science vol. 246, pp. 1275-1281 (1989). [cited by applicant]
Hwang et al., Use of human germline genes in a CDR homology-based approach to antibody humanization, Methods vol. 36(1), pp. 35-42 (2005). [cited by applicant]
International Preliminary Report on Patentability received in International Patent Application No. PCT/US2016/054222, dated Apr. 3, 2018. [cited by applicant]
International Search Report and Written Opinion received in International Patent Application No. PCT/US2016/054222, dated Mar. 10, 2017. [cited by applicant]
International Search Report and Written Opinion, mailed Feb. 5, 2018, received in International Patent Application No. PCT/US2017/048757. [cited by applicant]
Jakobovits et al., Analysis of homozygousmutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production, Proc. Natl. Acad. Sci. USA vol. 90, pp. 2551-25… [cited by applicant]
Jakobovits et al., Germ-line transmission and expression of a human-derived yeast artificial chromosome, Nature vol. 362, pp. 255-258 (1993). [cited by applicant]
Jakobovits, A., The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice, Exp. Opin. Invest. Drugs vol. 7, pp. 607-614 (1998). [cited by applicant]
Jakobovits, A., Production and Selection of antigen-specific fully human monoclonal antibodies from mice engineered with human Ig loci, Advanced Drug Delivery Reviews vol. 31, pp. 33-42 (1998). [cited by applicant]
Jakobovits, A., Humanizing the mouse genome, Curr. Biol. vol. 4, pp. 761-763 (1994). [cited by applicant]
Janssens et al. Generation of heavy-chain-only antibodies in mice, PNAS vol. 103, pp. 15130-15135; Harbour Biologics, Rotterdam, Netherlands 2006. [cited by applicant]
Jia et al., A novel method of Multiplexed Competitive Antibody Binning for the characterization of monoclonal antibodies, Journal of immunological Methods vol. 288, pp. 91-98 (2004). [cited by applicant]
Jones, D., Progress in protein structure prediction, Current Opinions on Structural Biology vol. 7(3), pp. 377-387 (1997). [cited by applicant]
Jorgensen et al., Loss-of-function mutations in APOC3 and risk of ischemic vascular disease, The New England journal of medicine vol. 371, pp. 32-41 (2014). [cited by applicant]
Kabat, E.A. et al., Sequences of Proteins of Immunological Interest, NIH, Bethesda, MD (1987 and 1991). [cited by applicant]
Kabat E.A. et al., Sequences of Proteins of Immunological Interest, NIH, Bethesda, MD (1991). [cited by applicant]
Kang et al., Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phase surfaces, Proc Natl. Acad Sci. USA vol. 88, pp. 363-366 (1991). [cited by applicant]
Kellerman et al., Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics, Current Opinion in Biotechnology vol. 13, pp. 593-597 (2002). [cited by applicant]
Kenneth et al., Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Plenum Press (1980). [cited by applicant]
Kohgo, Y., et al., Production and Characterization of Specific Asialoglycoprotein Receptor Antibodies, HYBRIDOMA, vol. 12, No. 5, pp. 591-598, (1993). [cited by applicant]
Kirkland et al., Analysis of the Fine Specificity and Cross-Reactivity of Monoclonal Anti-lipid A Antibodies, Journal of Immunology vol. 137, pp. 3614-3619 (1986). [cited by applicant]
Kohler, Immunoglobulin chain loss in hybridoma lines, Proc. Natl. Acad. Sci. USA vol. 77, pp. 2197 (1980). [cited by applicant]
Korndorfer et al., Crystallographic Analysis of an “Anticalin” with Tailored Specificity for Fluorescein Reveals High Structural Plasticity of the Lipocalin Loop Region, Proteins: Structure, Function, and Bioinformatics… [cited by applicant]
Kortt et al. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting, Biomol. Eng. vol. 18, pp. 95-108 (2001). [cited by applicant]
Kortt et al., Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five-and ten-residue linkers form dimers and with zero-residue linker a trimer, Protein Engineering vol. 10, pp. 423 (1997). [cited by applicant]
Kostelny et al., Formation of a Bispecific Antibody by the Use of Leucine Zippers, Journal of Immunology vol. 148, pp. 1547-1553 (1992). [cited by applicant]
Kriegler, M., Table of Contents of Gene Transfer and Expression, A Laboratory Manual, Stockton Press (1990). [cited by applicant]
Kriangkum et al., Bispecific and bifunctional single chain recombinant antibodies, Biomol. Eng. vol. 18, pp. 31-40 (2001). [cited by applicant]
Lam et al., A new type of synthetic peptide library for identifying ligand-binding activity, Nature vol. 354, pp. 82-84 (1991). [cited by applicant]
Landschulz et al., The Leucine Zipper: A Hypothetical Structural Common to a New Class of DNA Binding Proteins, Science vol. 240, pp. 1759 (1988). [cited by applicant]
Lanitto et al., Chain Shuffling to Modify Properties of Recombinant Immunoglobulins, Methods in Molecular Biology vol. 178, pp. 303-316 (2002). [cited by applicant]
Larock, Comprehensive Organic Transformations, VCH Publishers (1989). [cited by applicant]
Larrick et al., Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes from Single Hybridoma Cells, Bio/Technology vol. 7, pp. 934 (1989). [cited by applicant]
Larrick et al., Methods: A Companion to Methods in Enzymology vol. 2, pp. 106 (1991). [cited by applicant]
Lefranc et al., IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains, Dev. Comp. Immunol. vol. 29, pp. 185-203 (2005). [cited by applicant]
Lesk, Computational molecular biology, A. M., ed., Oxford University Press, (1988). [cited by applicant]
Lim et al., A diversity of antibody epitopes can induce signaling through the erythropoietin receptor, Biochemistry vol. 49, pp. 3797-3804 (2010). [cited by applicant]
Liu et al., Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells, Proc. Nat. Acad. Sci. USA vol. 84, pp. 3439 (1987). [cited by applicant]
Lonberg et al., Human Antibodies from Transgenic Mice, Internal Review of Immunology vol. 13, pp. 65-93 (1995). [cited by applicant]
Lonberg et al., Antigen-specific human antibodies from mice comprising four distinct genetic modifications, Nature vol. 368, pp. 856-859 (1994). [cited by applicant]
Lonberg, Transgenic Approaches to Human Monoclonal Antibodies in Handbook of Experimental Pharmacology vol. 113, pp. 49-101 (1994). [cited by applicant]
Low et al., Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophae Using a Bacterial Mutator Strain, Journal of Molecular Biology vol. 250, pp. 350-368 (1996). [cited by applicant]
Lowy et al., Isolation of Transforming DNA: Cloning the Hamster aprt Gene, Cell vol. 22, pp. 817 (1980). [cited by applicant]
Liu et al., A new splice variant of the major subunit of human asialogycoprotein receptor encodes a secreted form in hepatocytes PloS one, vol. 5, e12934 (2010). [cited by applicant]
Maniatis et al., Regulation of Inducible and Tissue-Specific Gene Expression, Science vol. 236, pp. 1237 (1987). [cited by applicant]
Manoharan, Oligonucleotide Conjugates in Antisense Technology, Antisense Drug Technology, ed. S. T. Crooke, Marcel Dekker, Inc. (2001). [cited by applicant]
Marks et al., By-passing Immunication: Building High Affinity Human Antibodies by Chain Shuffling, Bio/Technology vol. 10, pp. 779-783 (1992). [cited by applicant]
Massarelli et al., “Three-Dimensional Models of the Oligomeric Human Asialoglycoprotein Receptor (ASGP-R)”, International Journal of Molecular Sciences, vol. 11, No. 10, pp. 3867-3884, 2010. [cited by applicant]
McCoy et al., Phaser crystallographic software, Journal of applied crystallography vol. 40, pp. 658-674 (2007). [cited by applicant]
McMahan et al., A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types, EMBO J. vol. 10, pp. 2821 (1991). [cited by applicant]
Meier et al., Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor. Journal of molecular biology vol. 300, 857-865 (2000). [cited by applicant]
Mendez et al., Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice, Nat Gen. vol. 15, pp. 146-156 (1997). [cited by applicant]
Miller et al., Epitope binning of murine monoclonal antibodies by a multiplexed pairing assay, Journal of Immunological Methods vol. 365, pp. 118-125 (2011). [cited by applicant]
Moldenhauer et al., Identity of HML-1 Antigen on Intestinal Intraepithelial T Cells and B-ly7 Antigen on Hairy Cell Leukaemia, Scandinavian Journal of Immunology vol. 32, pp. 7-82 (1990). [cited by applicant]
Molecular Operating Environment (MOE), 08, Chemical Computing Group, Inc., (2013). [cited by applicant]
Morel et al., Monoclonal Antibodies to Bovine Serum Albumin: Affinity and Specificity Determinations, Molecular Immunology vol. 25, pp. 7-15 (1988). [cited by applicant]
Morell et al., The role of sialic acid in determining the survival of glycoproteins in the circulation, The Journal of biological chemistry vol. 246, pp. 1461-1467 (1971). [cited by applicant]
Morgan et al., Precise epitope mapping of malaria parasite inhibitory antibodies by TROSY NMR cross-saturation, Biochemistry vol. 44, pp. 518-523 (2005). [cited by applicant]
Moult, J., The current state of the art in protein structure prediction, Current Operations in Biotechnology vol. 7(4), pp. 422-427 (1996). [cited by applicant]
Mulligan et al., Selection for animal cells that express the [cited by applicant]
Nanevicz et al., Mechanisms of Thrombin Receptor Agonist Specificity, Journal of Biological Chemistry vol. 270(37), pp. 21619-21625 (1995). [cited by applicant]
Naramura et al., Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells, Immunol. Lett. vol. 39, pp. 91-99 (1994). [cited by applicant]
Neuberger, Generating high-avidity human Mabs in mice, Nature Biotechnology vol. 14, pp. 826 (1996). [cited by applicant]
Nioi et al., Variant ASGR1 Associated with a Reduced Risk of Coronary Artery Disease, The New England journal of medicine vol. 374, pp. 2131-2141, doi:10.1056/NEJMoa1508419 (2016). [cited by applicant]
Nisonoff et al., Separation of Univalent Fragments from the Bivalent Rabbit Antibody Molecule by Reduction of Disulfide Bonds, Arch. Biochem. Biophys. vol. 89, pp. 230 (1960). [cited by applicant]
Nygren and Uhlen, Scaffolds for engineering novel binding sites in proteins, Current Opinion in Structural Biology vol. 7, pp. 463-469 (1997). [cited by applicant]
O'Hare et al., Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase, Proc. Natl. Acad. Sci. USA vol. 78, pp. 1527 (1981). [cited by applicant]
Olafsen et al., Characterization of engineered anti-p185- [cited by applicant]
Olsen et al., N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population, European heart journal vol. 28, pp. 1374-1381 (2007… [cited by applicant]
Padlan et al., Identification of specificity-determining residues in antibodies, FASEB J. vol. 9, pp. 133-139 (1995). [cited by applicant]
Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995). [cited by applicant]
Paris et al. ASGR1 expressed by porcine enriched liver sinusoidal endothelial cells mediates human platelet phagocytosis in vitro, Xenotransplantation vol. 18, pp. 245-251, (2011). [cited by applicant]
Park et al., “Detection of Surface Asialoglycoprotein Receptor Expression in Hepatic and Extra-Hepatic Cells Using a Novel Monoclonal Aantibody,” Biotechnology Letters, vol. 28. No. 14, pp. 1061-1069, 2006. [cited by applicant]
Patten et al., Applications of DNA shuffling to pharmaceuticals and vaccines, Current Opinions in Biotechnology vol. 8, pp. 724-733 (1997). [cited by applicant]
Paul, ed., Fundamental Immunology, 4 [cited by applicant]
Paul, W., Fundamental Immunology Ch. 7, 2d ed., Raven Press, N.Y. (1989). [cited by applicant]
Poljak et al., Production and structure of diabodies, Structure vol. 2, pp. 1121-1123 (1994). [cited by applicant]
Porter, The Hydrolysis of Rabbit γ-Globulin and Antibodies with Crystalline Papain, Biochemistry Journal vol. 73, pp. 119 (1959). [cited by applicant]
Pouwels et al., Cloning Vectors: A Laboratory Manual, Elsevier (1985). [cited by applicant]
Powers et al., Expression of single-chain Fv-Fc fusions in Pichia pastoris, Journal of Immunological Methods vol. 251, pp. 123-135 (2001). [cited by applicant]
Proudfoot, Transcriptional interference and termination between duplicated α-globin gene constructs suggests a novel mechanism for gene regulation, Nature vol. 322, pp. 52 (1986). [cited by applicant]
Rajeev et al., Hepatocyte-Specific Delivery of siRNAs Conjugated to Novel Non-nucleosidic Trivalent N-Acetylgalactosamine Elicits Robust Gene Silencing in Vivo, ChemBiochem vol. 16(6), pp. 903-908 (2015). [cited by applicant]
Rasmussen et al., Isolation, characterization and recombinant protein expression in Veggie-CHO: A serum-free CHO host cell line, Cytotechnology vol. 28, pp. 31 (1998). [cited by applicant]
Rathanaswami et al., High-affinity binding measurements of antibodies to cell-surface-expressed antigens, Analytical Biochemistry vol. 373, pp. 52-60 (2008). [cited by applicant]
Riechmann et al., Reshaping human antibodies for therapy, Nature vol. 332, pp. 323 (1988). [cited by applicant]
Roggenbuck et al., Asialoglycoprotein receptor (ASGPR): a peculiar target of liver-specific autoimmunity, Autoimmune Highlights vol. 3, pp. 119-125 (2012). [cited by applicant]
Roque et al., Antibodies and Genetically Engineered Related Molecules: Production and Purification, Biotechnology Progress vol. 20, pp. 639-654 (2004). [cited by applicant]
Rotundo et al., Circulating Cellular Fibronectin May be a Natural Ligand for the Hepatic Asialoglycoprotein Receptor: Possible Pathway for Fibronectin Deposition and Turnover in the Rat Liver, Hepatology vol. 28, pp. 47… [cited by applicant]
Russel et al., Production of Protective Human Antipneumococcal Antibodies by Transgenic Mice with Human Immunoglobulin Loci, Infect Immun. vol. 68, pp. 1820-1826 (2000). [cited by applicant]
Sabrautzki et al., “New Mouse Models for Metabolic Bone Disease Generated by ENU Mutagenesis Genome-Wide ENU Mutagenesis,” Mammalian Genome, vol. 23, pp. 416-430, 2012. [cited by applicant]
Saitou and Nei, The Neighbor-joining Method: A New Method for Reconstructing Phylogenetic Trees Molecular Biology and Evolution vol. 4, pp. 406-425 (1987). [cited by applicant]
Samani et al., Genomewide association analysis of coronary artery disease, The New England journal of medicine vol. 357, pp. 443-453 (2007). [cited by applicant]
Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press. (1989). [cited by applicant]
Santerre et al., Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells, Gene vol. 30, pp. 147 (1984). [cited by applicant]
Sastry et al., Cloning of the immunological repertoire in [cited by applicant]
Schier et al., Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site, Journal of Molecular Biology vol… [cited by applicant]
Scholtens et al., A histochemical study on the distribution of injected canine intestinal alkaline phosphatase in rat liver, Liver vol. 2(1), pp. 14-21 (1982). [cited by applicant]
Sclebusch et al., Production of a Single-Chain Fragment of the Murine Anti-Idiotypic Antibody ACA125 as Phage-Displayed and Soluble Antibody by Recombinant Phage Antibody Technique, Hybridoma vol. 16, pp. 47-52 (1997). [cited by applicant]
Sham et al., Statistical power and significance testing in large-scale genetic studies, Nature reviews, Genetics vol. 15, 335-346, doi:10.1038/nrg3706 (2014). [cited by applicant]
Shimada, M. A monoclonal antibody to rat asialoglycoprotein receptor that recognizes an epitope specific to its major subunit, Hepatology Research, vol. 26, No. 1, pp. 55-60, (2003). [cited by applicant]
Simeoni et al., Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells, Nucl. Acids Res. vol. 31, pp. 2717-2724 (2003). [cited by applicant]
Sippl et al., Threading thrills and threats, Structure vol. 4(1), pp. 15-19 (1996). [cited by applicant]
Smith et al., Genetic Engineering: Principles and Methods, Plenum Press (1981). [cited by applicant]
Smith, Biocomputing: informatics and genome projects, ed., Academic Press, (1993). [cited by applicant]
Song et al., Epitope Mapping of Ibalizumab, a Humanized Anti-CD4 Monoclonal Antibody with Anti-HIV-1 Activity in Infected Patients, Journal of Virology vol. 84, pp. 6935-6942 (2010). [cited by applicant]
Songsivilai and Lachmann, Bispecific antibody: a tool for diagnosis and treatment of disease, Clinical Experimental Immunology vol. 79, pp. 315-321 (1990). [cited by applicant]
Stahli et al., Distinction of Epitopes by Monoclonal Antibodies, Methods in Enzymology vol. 9, pp. 242-253 (1983). [cited by applicant]
Stefanescu, R. et al., Epitope Structure of the Carbohydrate Recognition Domain of Asialoglycoprotein Receptor to a Monoclonal Antibody Revealed by High-Resolution Proteolytic Excision Mass Spectrometry, Journal of the … [cited by applicant]
Steinthorsdottir et al., Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of type 2 diabetes. Nature genetics vol. 46, pp. 294-298 (2014). [cited by applicant]
Steirer et al., The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid alpha2,6-galactose., The Journal of Biological Chemistry vol. 284, pp. 3777-3783 (2009). [cited by applicant]
Stockert et al., IgA interaction with asialoglycoprotein receptor, PNAS vol. 79, pp. 6229-6231 (1982). [cited by applicant]
Stockert et al., Hepatic Binding Protein: The Protective Role of its Sialic Acid Residues, Science vol. 197, pp. 667-668 (1977). [cited by applicant]
Subbarao et al., pH-Dependent Bilayer Destabilization by an Amphipathic Peptide, Biochemistry vol. 26, pp. 2964-2972 (1987). [cited by applicant]
Szybalska & Szybalski, Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait, Proc. Natl. Acad. Sci. USA vol. 48, pp. 202 (1992). [cited by applicant]
Tamura et al., “Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only,” The J… [cited by applicant]
Taylor et al., Human immunoglobuline transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM, International Immunology vol. 6, pp. 579-591 (1994). [cited by applicant]
Taylor et al., A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins, Nucleic Acid Research vol. 20, pp. 6287-6295 (1992). [cited by applicant]
Thompson et al. Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice, Nucleic Acids Res. vol. 22, pp. 4673-… [cited by applicant]
Thompson et al., Affinity Maturation of a High-Affinity Human Monoclonal Antibody Against the Third Hypervariable Loop of Human Immunodeficiency Virus: Use of Phase Display to Improve Affinity and Broaden Strain Reactiv… [cited by applicant]
Thornton et al., Prediction of progress at last, Nature vol. 354, pp. 105 (1991). [cited by applicant]
Timms KM, Wagner S, Samuels ME, et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Human genetics vol. 114, pp. 349-353 (2004). [cited by applicant]
Tomizuka et al., Functional expression and germline transmission of a human chromosome fragment in chimaeric mice, Nature Genetics vol. 16, pp. 133-143 (1997). [cited by applicant]
Tomizuka et al., Double trans-chromosomic mice: Maintenance of two individual human chromosome fragments containing Ig heavy and κ loci and expression of fully human antibodies, Proceedings of the National Academy of Sc… [cited by applicant]
Tozawa et al., Asialoglycoprotein receptor deficiency in mice lacking the major receptor subunit. It's obligate requirement for the stable expression of oligomeric receptor, The Journal of Biological Chemistry vol. 276,… [cited by applicant]
Trahtenherts et al., “An Internalizing Antibody Specific for the Human Asialoglycoprotein Receptor”, Hybridoma, vol. 28, No. 4, pp. 225-233, Nov. 4, 2009. [cited by applicant]
Trufert et al., Synthesis, Purification and Characterization of Two Peptide-Oligonucleotide Conjugates as Potential Artificial Nucleases, Tetrahedron vol. 52, pp. 3005 (1996). [cited by applicant]
Tsuda et al., Inactivation of the Mouse HPR Locus by a 203-bp Retroposon Insertion and a 55-kb Gene-Targeted Deletion: Establishment of New HPRT-Deficient Mouse Embryonic Stem Cell Lines, Genomics vol. 42, pp. 413-421 (… [cited by applicant]
Tuaillon et al., Biased Utilization of D [cited by applicant]
Tuaillon et al., Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: Gene-segment use in μ and γ transcripts, Proceedings of the National Academy of Sciences USA vol. 90, pp. 3720-3724 (1993). [cited by applicant]
Tuin et al., On the role and fate of LPS-dephosphorylating activity in the rat liver, American Journal of Physiology Gastrointestinal and Liver Physiology vol. 290, pp. 377-385 (2006). [cited by applicant]
Turk et al., Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs, Biochem. Biophys. Acta, vol. 1559, pp. 56-68 (2002). [cited by applicant]
Urlaub et al., Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity, Proc. Natl. Acad. Sci. USA vol. 77, pp. 4216-4220 (1980). [cited by applicant]